SCHEMBL23620552

SCHEMBL23620552

Cn1c(=O)n(C)c2nc(Cl)ncc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.56
HSD17B10 Q99714 2/20 0.56
HTT P42858 2/20 0.56
PDE3B Q13370 2/20 0.41
PDE3A Q14432 2/20 0.41
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
LMNA P02545 2/20 0.38
GSK3B P49841 1/20 0.38
JAK2 O60674 1/20 0.38
PAX8 Q06710 1/20 0.38
PIK3CD O00329 3/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
ADORA2A P29274 3/20 0.37
ADORA2B P29275 3/20 0.37
ADORA3 P0DMS8 2/20 0.37
ADORA1 P30542 2/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25057366 0.84 HSD17B10 (0.44) HPGDHSD17B10HTTLMNAGSK3B
SCHEMBL1781420 0.82 ADORA2B (0.43) HPGDHSD17B10HTTGSK3BPIK3CA
SCHEMBL4184831 0.78 HSD17B10 (0.39) HPGDHSD17B10HTTGSK3BPIK3CA
SCHEMBL29651071 0.78 GSK3B (0.64) HPGDHSD17B10HTTALDH1A1KDM4E
SCHEMBL8046579 0.78 HSD17B10 (0.47) HPGDHSD17B10HTTPDE3BPDE3A
SCHEMBL30328166 0.77 HPGD (0.38) HPGDHSD17B10HTT
SCHEMBL28821218 0.77 PRKDC (0.43) HPGDHSD17B10HTTPIK3CA
SCHEMBL10006721 0.77 HPGD (0.38) HPGDHSD17B10HTTALDH1A1KMT2A
SCHEMBL1780155 0.77 PRKDC (0.52) PIK3CA
SCHEMBL4184836 0.77 PDE4A (0.43) HPGDHSD17B10HTTLMNAADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239790-A1 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor LIFEARC (GB) 2024-07-18 US disclosed
US-20240239790-A1 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor LIFEARC (GB) 2024-07-18 US disclosed
US-20240239790-A1 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor LIFEARC (GB) 2024-07-18 US disclosed
EP-4305032-A1 7-MORPHOLINO-1,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR Admare Therapeutics Society (CA) 2024-01-17 EP disclosed
WO-2022187965-A1 7-MORPHOLINO-1,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR adMare Therapeutics Society (CA) 2022-09-15 WO disclosed
WO-2021136462-A1 FURAN DERIVATIVES AND APPLICATION THEREOF IN MEDICINE 成都百裕制药股份有限公司 2021-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239790-A1 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor DCK, ERCC2, POLK HPGD 826/4885HSD17B10 2876/4885HTT 4239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.